Emerging delivery technologies Beyond sublingual drops, researchers are exploring other needle-free tirzepatide delivery methods including: Transdermal patches using microneedle technology that could deliver peptides through the skin
Semaglutide injections offer a promising solution if you have ongoing struggles with weight management
4 , 5 This uncertainty in DDI potential is particularly problematic when initiating GLP1RA therapy in patients taking narrow therapeutic index medications, such as oral anticoagulants, anticonvulsants, and hormonal contraceptives
In addition, intensive research focused on biological targets which could stimulate GLP-1 release in the gut or pancreas, including GPR120, SSTR5, GPR40, TGR-5 and GPR119
And I feel like thats also another very interesting point
"The Medicare GLP-1 Bridge changes that by making these medications more affordable and accessible, while advancing our broader goal of helping Americans live healthier lives." An estimated 3.8 million beneficiaries could be eligible for the program, according to a KFF analysis of 2023 Part D enrollment data that was published Monday
.png)
